BMY Stock Down -6.3% after 8-Day Loss Streak
Bristol-Myers Squibb (BMY) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -6.3% return. The company has lost about $5.6 Bil in value over the last 8 days, with its current market capitalization at about $88 Bil. The stock remains 21.6% below its value at the end of 2024. This compares with year-to-date returns of 12.3% for the S&P 500.
BMY provides biopharmaceutical products worldwide, specializing in hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 treatments, including Revlimid for multiple myeloma. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell BMY.
Comparing BMY Stock Returns With The S&P 500
The following table summarizes the return for BMY stock vs. the S&P 500 index over different periods, including the current streak:
- Market Leader Bristol-Myers Squibb Stock at 21% Discount, Worth Buying?
- Is Bristol Myers Squibb Undervalued?
- BMY Stock Down -12% after 6-Day Loss Streak
- Is It Time To Buy Bristol Myers Squibb Stock?
- How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
- Is Bristol-Myers Squibb Stock A Safe Haven During Tariff Turmoil?
| Return Period | BMY | S&P 500 |
|---|---|---|
| 1D | -1.7% | -0.5% |
| 8D (Current Streak) | -6.3% | -0.2% |
| 1M (21D) | -8.0% | 2.1% |
| 3M (63D) | -6.9% | 7.6% |
| YTD 2025 | -21.6% | 12.3% |
| 2024 | 15.8% | 23.3% |
| 2023 | -26.1% | 24.2% |
| 2022 | 19.0% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 45 S&P constituents with 3 days or more of consecutive gains and 113 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 28 | 58 |
| 4D | 8 | 17 |
| 5D | 3 | 27 |
| 6D | 3 | 5 |
| 7D or more | 3 | 6 |
| Total >=3 D | 45 | 113 |
Key Financials for Bristol-Myers Squibb (BMY)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $45.0 Bil | $48.3 Bil |
| Operating Income | $8.2 Bil | $5.9 Bil |
| Net Income | $8.0 Bil | $-8.9 Bil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $12.3 Bil | $11.2 Bil |
| Operating Income | $510.0 Mil | $3.5 Bil |
| Net Income | $72.0 Mil | $2.5 Bil |
The losing streak BMY stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.